Chemical inhibitors of Neuropeptide FF (NPFF) function through various mechanisms to block or modulate the signaling pathways in which NPFF is involved. One direct method of inhibition is through the use of RF9, which acts as a selective antagonist to NPFF receptors. By binding to NPFFR1 and NPFFR2, RF9 prevents NPFF from activating these receptors, effectively halting the biological effects that would normally follow NPFF receptor activation. Similarly, J 113397 targets the opioid receptor-like 1 (ORL1) receptors, which have overlapping expression patterns with NPFF receptors. By antagonizing ORL1 receptors, J 113397 can indirectly influence NPFF signaling due to the shared modulation of certain pain pathways between NPFF and ORL1 receptors.
Other inhibitors act on pathways that are indirectly related to NPFF signaling. For example, BIBP 3226, a selective neuropeptide Y1 receptor antagonist, can alter NPFF function since NPFF and neuropeptide Y receptors can co-express and interact within the same pathways. Yohimbine and Phenoxybenzamine target alpha-2 and alpha-adrenergic receptors, respectively. By blocking these receptors, these compounds can disrupt downstream effects of NPFF that involve adrenergic signaling. L-NAME, by inhibiting nitric oxide synthase, reduces the production of nitric oxide, which is a modulator of pain pathways where NPFF is known to be active. The serotonin receptor antagonists Ketanserin, GR 127935, Methysergide, SB 224289, and SB 206553 interfere with various serotonin receptors that NPFF may modulate. Ketanserin, for example, blocks serotonin 2A receptors, while GR 127935 selectively antagonizes serotonin 5-HT1B/1D receptors, and SB 206553 blocks serotonin 5-HT2B/2C receptors. Additionally, CP 93129, as a serotonin 5-HT1B receptor agonist, can influence neurotransmitter release in pain pathways affected by NPFF. Each of these chemical inhibitors, through their respective targets, can lead to the functional inhibition of NPFF by disrupting signaling pathways in which NPFF plays a modulatory role.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Yohimbine hydrochloride | 65-19-0 | sc-204412 sc-204412A sc-204412B | 1 g 5 g 25 g | $50.00 $168.00 $520.00 | 2 | |
Yohimbine is an alpha-2 adrenergic receptor antagonist. Since NPFF can modulate adrenergic receptor activity, blocking these receptors with Yohimbine can interfere with the downstream effects of NPFF, leading to its functional inhibition. | ||||||
L-NG-Nitroarginine Methyl Ester (L-NAME) | 51298-62-5 | sc-200333 sc-200333A sc-200333B | 1 g 5 g 25 g | $47.00 $105.00 $322.00 | 45 | |
L-NAME is a nitric oxide synthase inhibitor. Nitric oxide can modulate pain pathways in which NPFF is involved. Inhibition of nitric oxide production by L-NAME can therefore lead to the functional inhibition of NPFF's role in these pathways. | ||||||
Ketanserin | 74050-98-9 | sc-279249 | 1 g | $700.00 | ||
Ketanserin is a serotonin receptor antagonist, which can block serotonin 2A receptors. As NPFF can modulate serotonergic signaling, inhibition of these receptors by Ketanserin can lead to indirect functional inhibition of NPFF. | ||||||